Solanezumab Fails Phase 3 Alzheimer’s Trials: Retains Faint Glimmer of Hope
...Now, Eli Lilly has also announced that their contribution to the Alzheimer’s battle, solanezumab, did not meet the primary endpoints, both cognitive and functional, in either of the two Phase 3, double-blind, placebo-controlled studies on the drug. read more..
No comments:
Post a Comment